These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3091287)

  • 1. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
    Cercek B; Lew AS; Hod H; Yano J; Reddy NK; Ganz W
    Circulation; 1986 Sep; 74(3):583-7. PubMed ID: 3091287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
    Cercek B; Lew AS; Hod H; Yano J; Lewis B; Reddy KN; Ganz W
    Thromb Res; 1987 Aug; 47(4):417-26. PubMed ID: 3660351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
    Rapold HJ; Lu HR; Wu ZM; Nijs H; Collen D
    Blood; 1991 Mar; 77(5):1020-4. PubMed ID: 1899806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Blood; 1990 Nov; 76(10):2030-6. PubMed ID: 2122919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus thrombolysis in venous thromboembolism.
    Agnelli G; Parise P
    Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study.
    Tomaru T; Uchida Y; Nakamura F; Sonoki H; Tsukamoto M; Sugimoto T
    Am Heart J; 1989 Feb; 117(2):275-81. PubMed ID: 2492737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
    Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
    Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats.
    Loren M; García Frade LJ; Torrado MC; Navarro JL
    Thromb Res; 1989 Oct; 56(1):67-75. PubMed ID: 2512687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
    Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M
    Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
    Rauber K; Heidinger KS; Kemkes-Matthes B
    Cardiovasc Intervent Radiol; 1997; 20(3):169-73. PubMed ID: 9134838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective decrease in lysis of old thrombi after rapid administration of tissue-type plasminogen activator.
    Kanamasa K; Watanabe I; Cercek B; Yano J; Fishbein MC; Ganz W
    J Am Coll Cardiol; 1989 Nov; 14(5):1359-64. PubMed ID: 2509530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.